CRISPR Therapeutics AG

Latest Report Overview

CRISPR Therapeutics AG (CRSP) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $10 million with diluted EPS of $-0.94 and net income of $-91 million. Operating margin was -1127.6%, and free cash flow was $-87 million for the period. Management continues to prioritize the commercialization of its lead asset, Casgevy, while simultaneously advancing its broader pipeline in oncology and autoimmune diseases. The balance sheet remains well-capitalized to support these long-term R&D investments, as evidenced by a healthy cash position, though operational losses remain high. The company's strategic focus is heavily aligned with its ongoing collaboration with Vertex Pharmaceuticals, which acts as the primary mechanism for mitigating the financial burden of clinical development and commercial launch execution. Guidance and forward outlook remain focused on clinical trial enrollment milestones and regulatory submissions across global markets. The firm is actively managing its operating expenses, balancing the aggressive R&D requirements of next-generation gene-editing candidates with the capital-intensive nature of commercial-stage operations, aiming to optimize its cash runway while scaling internal capabilities.

Key Takeaways for CRISPR Therapeutics AG

• CRISPR Therapeutics reported Q2 2026 revenue of $10.18 million, representing a 1041.4% YoY increase driven by specific milestone payments from its ongoing collaboration with Vertex.
• The company maintains a significant R&D-led cost structure, with Q2 2026 R&D expenses totaling $67.15 million, reflecting the firm's continued investment in its proprietary gene-editing platform.
• Net loss for the quarter was $91.15 million, highlighting the persistent cash burn characteristic of a clinical and early-commercial stage biotechnology firm.
• Management continues to focus on the global commercial rollout of Casgevy, which serves as a pivotal proof-of-concept and revenue anchor for the company's long-term commercialization strategy.
• The firm exhibits a strong liquidity position, with a current ratio of 17.85, providing a buffer for ongoing operational costs despite the absence of sustained, organic product revenue.
• Intellectual property and clinical milestone execution remain the primary existential variables for the company's valuation, given the binary nature of therapeutic regulatory approvals.

What Does CRISPR Therapeutics AG Do?

CRISPR Therapeutics is a gene-editing biotechnology company focused on the development of transformative, gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 platform. The company's platform allows for precise, directed changes to genomic DNA, with the goal of creating one-time, curative therapies. Its primary commercial product, Casgevy, is developed in collaboration with Vertex Pharmaceuticals and is designed to treat sickle cell disease and transfusion-dependent beta-thalassemia. Beyond Casgevy, the company maintains a robust pipeline of product candidates targeting hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo applications. The company operates globally, primarily serving healthcare markets where there is a high unmet need for curative therapeutic interventions. Scale is indicated by its extensive R&D-heavy cost structure and strategic partnerships with major pharmaceutical players.

Growth Drivers for CRISPR Therapeutics AG

• Continued successful commercial rollout of Casgevy across additional global jurisdictions.
• Advancement of oncology pipeline candidates into later-stage clinical trials.
• Execution of milestone events in collaborations with Vertex and other partners, which provide non-dilutive capital.
• Expansion of the CRISPR/Cas9 platform into in vivo indications, targeting a wider range of genetic diseases.
• Potential for new strategic partnerships to fund the development of early-stage therapeutic candidates.